https://www.selleckchem.com/products/rbn-2397.html
Papillary thyroid cancer (PTC) has a high incidence of BRAF mutation. The purpose of this study was to evaluate the potential relationship between thyroiditis and BRAF mutation status in patients with PTC. We investigated how a selective inhibitor of BRAF PLX4032 affects the proliferation and inflammatory cytokine levels of thyroid cancer. Two thyroid cancer cell lines TPC1 and 8505C were treated with PLX4032, an analysis was done on cell growth, cell cycle, the degree of apoptosis, and levels of inflammatory cytokines. To identify the
Curtir
Comentario
Compartilhar
